SUBSCRIBE
SUBSCRIBE

Jennifer C. Smith-Parker

Director of Insights

Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.

Insights
Can we finally get ahead of drug shortages?
In this episode of Denatured, you’ll hear from Christina Smolke, co-founder & CEO at Antheia and Kyle Pudenz, senior vice president and head of data & AI product at Cencora. We explore why drug shortages are getting worse, and how combining predictive supply-chain analytics with agile, distributed manufacturing could finally make essential medicines more resilient and accessible.
November 12, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
IN PARTNERSHIP WITH SK pharmteco
Before GMP: Six manufacturing considerations gene therapy sponsors should address earlier
SK pharmteco’s Tatiana Nanda, chief technical officer of SK pharmteco Viral Vector North America discusses what gene therapy sponsors must account for sooner rather than later when preparing for GMP manufacturing.
November 9, 2026
 · 
6 min read
 · 
Jennifer C. Smith-Parker
Insights
Beyond the needle: The future of intratumoral therapy
In this episode of Denatured, you’ll hear from from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies trigger systemic anticancer immunity from a local injection, and redefine a foundational platform in immuno-oncology.
November 5, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Wind up Earth globe green-blue pastel color on pink background. Designed in minimal concept. 3D Render.
Drug Development
Can Saudi Arabia’s burgeoning biotech hub withstand geopolitical pressures?
Saudi Arabia is building the regulatory framework, partnerships infrastructure and IP landscape needed to support a biotech ecosystem, despite regional political instability. Whether it can produce sustainable biotech companies and a resilient manufacturing base for global production remains an open question, but the future looks bright.
November 2, 2026
 · 
6 min read
 · 
Jennifer C. Smith-Parker
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role.
October 29, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Insights
Australia’s clinical trial advantage gains ground amid U.S. uncertainty
CROs cite faster startup timelines, regulatory predictability and tax incentives as reasons for growing interest in Australia. State investments in manufacturing, translational research and advanced therapies aim to expand that advantage into a broader biotech ecosystem. The question remains whether Australia can support drug development at broader scale.
October 26, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Insights
Why investors are taking another look at kidney disease
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.
October 22, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Creative collage human 3d hands body fragments needle injection gloves medical healthcare hospital virus prevention drawing background.
Insights
More arms, more questions: The new challenge in multispecific drug design
As trispecifics, cell engagers and other complex formats multiply, drug developers are seeking discovery and engineering partners to help navigate an expanding universe of molecular possibilities.
October 19, 2026
 · 
5 min read
 · 
Jennifer C. Smith-Parker
IN PARTNERSHIP WITH CYTIVA
The decisions behind scientific progress
In this episode of Denatured, presented by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we explore how biopharma’s real bottleneck isn’t too little data—it’s too little confidence in the decisions that drive development, manufacturing and commercialization.
October 15, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
IN PARTNERSHIP WITH ROSE BIOSOLUTIONS
Successful CDMO partnerships hinge on honest—and sometimes critical—support
CDMO-sponsor relationships have shifted from transactional outsourcing to strategic collaboration built on shared risk, regulatory fluency and technical insight. As rising compliance pressure and geopolitical volatility reshape manufacturing, partners like Rose BioSolutions argue that true value now comes from challenging assumptions, anticipating hurdles and protecting programs before problems surface.
October 12, 2026
 · 
5 min read
 · 
Jennifer C. Smith-Parker
Insights
Beyond equity: Why venture debt is reshaping European biotech
In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.
October 8, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Insights
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
A surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoid CROs, service providers are scaling and diversifying as global sponsors turn to Swiss hubs for talent, innovation and regulatory strength.
October 5, 2026
 · 
6 min read
 · 
Jennifer C. Smith-Parker
Insights
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.
October 1, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Pictured: 3D illustration of stem cells used for cell therapy
IN PARTNERSHIP WITH LONGEVITY MEDICAL INSTITUTE
Regenerative medicine needs more than stem cells
Stem cell therapies vary widely yet many physicians still treat them as interchangeable. A more credible model requires diagnostics, product characterization and conventional medical context to determine who and when should receive regenerative treatment.
September 28, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker
Overcoming business challenge and obstacles. Business success. Achievement and goals concept.
Insights
After COVID, biomanufacturing tackles preparedness and commercialization challenges
Manufacturers are redesigning their processes to balance both better future emergency vaccine mobilization and the more demanding work of maintaining flexible, commercially viable manufacturing networks.
September 25, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker